Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 285 posts found.

BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme

May 10, 2019
Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News

BMS scores expanded European approval for Sprycel in paediatric leukaemia

February 13, 2019
Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma

Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …

News

Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application

January 25, 2019
Medical Communications BMS, Merck, Yervoy, ctla4, lung cancer, opdivo

Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer. …

News
shutterstock_273326141

BMS to acquire Celgene for $74 billion in biggest-ever pharma deal

January 4, 2019
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, acquisition, pharma

Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of …

News
bmssyracuseny

Taisho Pharma to buy Bristol-Myers Squibb’s consumer health business in deal worth $1.6 bn

December 19, 2018
Business Services BMS, Japan, M&A, MA, Taisho, deal

Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business. With more than a …

News
bms_nassau_park_new_jersey

CHMP approve Bristol-Myers Squibb’s Sprycel for paediatric patients with Ph+ ALL

December 17, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Sprycel, all

New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the …

News
opdivo_1_1

Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

November 30, 2018
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …

News

FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival

November 7, 2018
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma

The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …

News

BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

October 22, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …

News

GSK named third best UK workplace

October 22, 2018
Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …

News
merckwindow_web

MSD to launch Keytruda at half US list price in China

September 20, 2018
Business Services, Sales and Marketing BMS, China, MSD, global, keytruda, markets, pricing

US pharma giant MSD will offer cutting edge cancer treatment Keytruda to Chinese patients at half the price at what …

News
john_nason

Teva names new President, TAPI and Biologics Operations

September 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Novartis, Teva, appointment

Israeli generic drug specialist Teva has announced its appointment of John Nason in a multi-faceted role as President of Teva …

Appointment

BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2

September 12, 2018
Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis

Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …

News
opdivo_1_1

BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy

September 10, 2018
Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma

Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023